Named-Patients Program
NPP-Menkes
Menkes International · Experimental Treatment Program
NPP-Menkes is an experimental treatment program using Elesclomol-Copper (ES-Cu) for children with Menkes disease, completely free of charge. Launched in 2020 and coordinated by Menkes International, it operates under authorisation by AEMPS (Spain) and Swissmedic (Switzerland).
9
Children under treatment
as of Jan 2026
as of Jan 2026
7
In Spain
(AEMPS authorised)
(AEMPS authorised)
2
In Switzerland
(Swissmedic authorised)
(Swissmedic authorised)
What Menkes International provides
- Active Pharmaceutical Ingredient (API) donated free of charge
- Scientific and clinical advice through the Copperless Committee
- Coordination with hospitals for drug formulation
- Support to families
How to access
1
Formal request by the physician and family to MICu
2
Approval by the hospital Ethics Committee
3
Authorization by the national medicines agency